Pneumocystis jirovecii infection: An emerging threat to patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2120-2130

  Mori, Shunsuke ^a   Sugimoto, Mineharu ^b  

^a NHO Kumamoto Saishunsou National Hospital   (Japan)

^b Social Ins Omuta Tenryo Hospital   (Japan)

Author keywords

Colonization; Outbreaks; Pneumocystis jirovecii; Prophylaxis; Rheumatoid rthritis; Transmission

Indexed keywords

ABATACEPT; ADALIMUMAB; COTRIMOXAZOLE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PENTAMIDINE ISETHIONATE; TACROLIMUS; TOCILIZUMAB;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL COLONIZATION; DISEASE ASSOCIATION; DISEASE CARRIER; DISEASE TRANSMISSION; EPIDEMIC; ERADICATION THERAPY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; KIDNEY GRAFT; LUNG DISEASE; MORTALITY; NONHUMAN; OUTPATIENT DEPARTMENT; PNEUMOCYSTIS JIROVECII INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFECTIVE AGENTS; ARTHRITIS, RHEUMATOID; CONTACT TRACING; DISEASE RESERVOIRS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSIVE AGENTS; INFECTIOUS DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; KIDNEY TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84870312839     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes244     Document Type: Review

References (146)

1. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Stenger AA, Houtman PM, Bruyn GA, Eggink HF, Pasma HR. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994;23:51-3.
4. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994;150:258-60.
5. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002;41:951-2.
6. Mori S, Imamura F, Kiyofuji C et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol 2006;16:58-62.
7. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis 2004;4:42.
8. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46: 2287-93.
9. Stringer JR, Beard CB, Miller RF. Spelling Pneumocystis jirovecii. Emerg Infect Dis 2009;15:506.
10. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891-6.
11. Tokuda H, Sakai F, Yamada H et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008;47:915-23.
12. Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol 2010;37:1547-8.
13. Vanek J, Jirovec O. [Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by pneumocystis Carinii.]. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1952;158:120-7.
14. Gajdusek DC. Pneumocystis carinii: etiologic agent of interstitial plasma cell pneumonia of premature and young infants. Pediatrics 1957;19:543-65.
15. Post C, Dutz W, Nasarian I. Endemic Pneumocystis carinii pneumonia in south Iran. Arch Dis Child 1964;39: 35-40.
16. Dutz W, Post C, Vessal K, Kohout E. Endemic infantile pneumocystis carinii infection: the Shiraz study. Natl Cancer Inst Monogr 1976;43:31-40.
17. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975;36:2004-9.
18. Walzer PD, Schultz MG, Western KA, Robbins JF. Pneumocystis carinii pneumonia and primary immune deficiency diseases. Natl Cancer Inst Monogr 1976;43: 65-74.
19. Hughes WT, Kuhn S, Chaudhary S et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26.
20. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1:175-82.
21. Chien SM, Rawji M, Mintz S, Rachlis A, Chan CK. Changes in hospital admissions pattern in patients with human immunodeficiency virus infection in the era of Pneumocystis carinii prophylaxis. Chest 1992; 102:1035-9.
22. Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl. 1): S5-14.
23. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl. 2): S416-22.
24. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995;155:1125-8.
25. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993: an analysis of 78 cases. Arch Intern Med 1995;155: 2436-41.
26. Nuesch R, Bellini C, Zimmerli W. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis 1999;29:1519-23.
27. Roblot F, Godet C, Le Moal G et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002; 21:523-31.
28. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007;39: 589-95.
29. Hahn PY, Limper AH. The role of inflammation in respiratory impairment during Pneumocystis carinii pneumonia. Semin Respir Infect 2003;18:40-7.
30. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000; 164:3755-63.
31. Walzer PD, LaBine M, Redington TJ, Cushion MT. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol 1984;133:2502-8.
32. Godeau B, Coutant-Perronne V, Le Thi Huong D et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21:246-51.
33. Saito K, Nakayamada S, Nakano K et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology 2004;43:479-85.
34. Sato T, Inokuma S, Maezawa R et al. Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases. Mod Rheumatol 2005;15: 191-7.
35. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13.
36. Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 2005; 15:91-6.
37. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006;16:282-8.
38. Wu AK, Cheng VC, Tang BS et al. The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis 2004;4:57.
39. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999;104:1307-17.
40. Enomoto T, Azuma A, Kohno A et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology 2010;15:126-31.
41. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
42. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906.
43. Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2011, Advance access published 13 Oct 2011, doi: 10.1007/s10165-011-0541-5.
44. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52:1481-4.
45. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70: 2148-51.
46. Mori S, Cho I, Ichiyasu H, Sugimoto M. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod Rheumatol 2008;18:240-6.
47. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am 2010;24:107-38.
48. Kovacs JA, Hiemenz JW, Macher AM et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100: 663-71.
49. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140: 1204-9.
50. Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung 2010;188: 159-63.
51. Tasaka S, Tokuda H, Sakai F et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 2010;49:273-81.
52. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999;42:780-9.
53. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978;61: 35-41.
54. Vargas SL, Hughes WT, Santolaya ME et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32: 855-61.
55. Beard CB, Carter JL, Keely SP et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis 2000;6:265-72.
56. Montes-Cano MA, de la Horra C, Martin-Juan J et al. Pneumocystis jiroveci genotypes in the Spanish population. Clin Infect Dis 2004;39:123-8.
57. Miller RF, Lindley AR, Copas A, Ambrose HE, Davies RJ, Wakefield AE. Genotypic variation in Pneumocystis jirovecii isolates in Britain. Thorax 2005;60:679-82.
58. Dohn MN, White ML, Vigdorth EM et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000;162: 1617-21.
59. Morris AM, Swanson M, Ha H, Huang L. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am J Respir Crit Care Med 2000;162:1622-6.
60. Beck JM. Pneumocystis carinii and geographic clustering: evidence for transmission of infection. Am J Respir Crit Care Med 2000;162:1605-6.
61. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995;172:595-8.
62. Keely SP, Baughman RP, Smulian AG, Dohn MN, Stringer JR. Source of Pneumocystis carinii in recurrent episodes of pneumonia in AIDS patients. AIDS 1996;10: 881-8.
63. Latouche S, Poirot JL, Bertrand V, Roux P. Pneumocystis carinii hominis sequencing for reactivation or de novo contamination and for hypothetic transmission from person to person. APMIS Suppl 1997; 77:11-3.
64. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 1997;35: 2745-7.
65. O'Donnell WJ, Pieciak W, Chertow GM, Sanabria J, Lahive KC. Clearance of Pneumocystis carinii cysts in acute P. carinii pneumonia: assessment by serial sputum induction. Chest 1998;114:1264-8.
66. Wakefield AE, Lindley AR, Ambrose HE, Denis CM, Miller RF. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 2003;187:901-8.
67. Sepkowitz K, Schluger N, Godwin T, Armstrong D, Cerami A, Bucala R. DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states. J Infect Dis 1993;168:421-6.
68. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun 1993;61:5406-9.
69. Vargas SL, Hughes WT, Wakefield AE, Oz HS. Limited persistence in and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia. J Infect Dis 1995;172:506-10.
70. Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998;91:813-20.
71. Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003;9: 132-4.
72. Olsson M, Eriksson BM, Elvin K, Strandberg M, Wahlgren M. Genotypes of clustered cases of Pneumocystis carinii pneumonia. Scand J Infect Dis 2001; 33:285-9.
73. Latouche S, Poirot JL, Maury E, Bertrand V, Roux P. Pneumocystis carinii hominis sequencing to study hypothetical person-to-person transmission. AIDS 1997; 11:549.
74. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 1996;34: 1754-9.
75. Olsson M, Lidman C, Latouche S et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998; 36:1737-40.
76. Bartlett MS, Vermund SH, Jacobs R et al. Detection of Pneumocystis carinii DNA in air samples: likely environmental risk to susceptible persons. J Clin Microbiol 1997; 35:2511-3.
77. Choukri F, Menotti J, Sarfati C et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010;51:259-65.
78. Damiani C, Choukri F, Le Gal S et al. Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis 2012;18:877-8.
79. Powles MA, McFadden DC, Pittarelli LA, Schmatz DM. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect Immun 1992;60:1397-400.
80. Dumoulin A, Mazars E, Seguy N et al. Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000;19:671-8.
81. Chabe M, Dei-Cas E, Creusy C et al. Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and RT-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis 2004;23:89-97.
82. Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993;61: 2886-90.
83. Durand-Joly I, Aliouat el M, Recourt C et al. Pneumocystis carinii f. sp. hominis is not infectious for SCID mice. J Clin Microbiol 2002;40:1862-5.
84. Stringer JR, Stringer SL, Zhang J, Baughman R, Smulian AG, Cushion MT. Molecular genetic distinction of Pneumocystis carinii from rats and humans. J Eukaryot Microbiol 1993;40:733-41.
85. Sloand E, Laughon B, Armstrong M et al. The challenge of Pneumocystis carinii culture. J Eukaryot Microbiol 1993; 40:188-95.
86. Morris A, Kingsley LA, Groner G, Lebedeva IP, Beard CB, Norris KA. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 2004;18:793-8.
87. Davis JL, Welsh DA, Beard CB et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax 2008; 63:329-34.
88. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010;50:347-53.
89. Medrano FJ, Montes-Cano M, Conde M et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005;11:245-50.
90. Vargas SL, Pizarro P, Lopez-Vieyra M, Neira-Aviles P, Bustamante R, Ponce CA. Pneumocystis colonization in older adults and diagnostic yield of single versus paired noninvasive respiratory sampling. Clin Infect Dis 2010;50: e19-21.
91. Totet A, Respaldiza N, Pautard JC, Raccurt C, Nevez G. Pneumocystis jiroveci genotypes and primary infection. Clin Infect Dis 2003;36:1340-2.
92. Vargas SL, Ponce CA, Gigliotti F et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000;38:1536-8.
93. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001;39:3877-82.
94. Lundgren B, Elvin K, Rothman LP, Ljungstrom I, Lidman C, Lundgren JD. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 1997; 52:422-4.
95. Calderon EJ, Regordan C, Medrano FJ, Ollero M, Varela JM. Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet 1996;347:977.
96. Armbruster C, Hassl A, Kriwanek S. Pneumocystis carinii colonization in the absence of immunosuppression. Scand J Infect Dis 1997;29:591-3.
97. Sing A, Roggenkamp A, Autenrieth IB, Heesemann J. Pneumocystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR. J Clin Microbiol 1999;37: 3409-10.
98. Probst M, Ries H, Schmidt-Wieland T, Serr A. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000;19:644-5.
99. Sing A, Geiger AM, Hogardt M, Heesemann J. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol 2001;39:2717-8.
100. Calderon E, de la Horra C, Medrano FJ et al. Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. Eur J Clin Microbiol Infect Dis 2004;23:545-9.
101. Respaldiza N, Montes-Cano MA, Dapena FJ et al. Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain. Clin Microbiol Infect 2005;11:1012-5.
102. Vidal S, de la Horra C, Martin J et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect 2006;12:231-5.
103. Helweg-Larsen J, Jensen JS, Dohn B, Benfield TL, Lundgren B. Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia-a case-control study. BMC Infect Dis 2002;2:28.
104. Maskell NA, Waine DJ, Lindley A et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003;58: 594-7.
105. Montes-Cano MA, de la Horra C, Dapena FJ et al. Dynamic colonisation by different Pneumocystis jirovecii genotypes in cystic fibrosis patients. Clin Microbiol Infect 2007;13:1008-11.
106. Rivero L, de la Horra C, Montes-Cano MA et al. Pneumocystis jirovecii transmission from immunocompetent carriers to infant. Emerg Infect Dis 2008;14: 1116-8.
107. Morris A, Sciurba FC, Lebedeva IP et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004;170:408-13.
108. Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008;35:1513-21.
109. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 2011; 21:164-73.
110. Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS 1999;13:535-6.
111. Hauser PM, Blanc DS, Bille J, Nahimana A, Francioli P. Carriage of Pneumocystis carinii by immunosuppressed patients and molecular typing of the organisms. AIDS 2000;14:461-3.
112. Nevez G, Pruna A, Jounieaux V, Makdassi R, Totet A, Raccurt C. A search for Pneumocystis carinii DNA by polymerase chain reaction on bronchoalveolar lavage fluids from patients with Wegener's granulomatosis. Rheumatology 1999;38:1025-7.
113. Mekinian A, Durand-Joly I, Hatron PY et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology 2010;50: 569-77.
114. Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T cell counts. Clin Infect Dis 1999;29:1331-2.
115. Fritzsche C, Riebold D, Munk-Hartig A, Klammt S, Neeck G, Reisinger E. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 2012, Advance access published 9 March 2012, doi: 10.3109/03009742.2011.630328.
116. Wissmann G, Morilla R, Martin-Garrido I et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest 2011;41:343-8.
117. de Boer MG, de Fijter JW, Kroon FP. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2010; 49:673-80.
118. Chave JP, David S, Wauters JP, Van Melle G, Francioli P. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant recipients. AIDS 1991;5:927-32.
119. Rabodonirina M, Vanhems P, Couray-Targe S et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004;10:1766-73.
120. Hocker B, Wendt C, Nahimana A, Tonshoff B, Hauser PM. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005;11:330-2.
121. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007;44: 1143-9.
122. Schmoldt S, Schuhegger R, Wendler T et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008;46:966-71.
123. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009;88:380-5.
124. Gianella S, Haeberli L, Joos B et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010;12:1-10.
125. Phipps LM, Chen SC, Kable K et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation 2011; 92:1327-34.
126. Ripamonti C, Orenstein A, Kutty G et al. Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jirovecii isolates. J Infect Dis 2009;200:1616-22.
127. Thomas S, Vivancos R, Corless C, Wood G, Beeching NJ, Beadsworth MB. Increasing frequency of Pneumocystis jirovecii pneumonia in renal transplant recipients in the United Kingdom: clonal variability, clusters, and geographic location. Clin Infect Dis 2011; 53:307-8.
128. Sassi M, Ripamonti C, Mueller NJ et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012;54: 1437-44.
129. Le Gal S, Damiani C, Rouille A et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012;54:e62-71.
130. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009;36:1600-5.
131. Kameda H, Tokuda H, Sakai F et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011;50:305-13.
132. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000;342:1416-29.
133. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1999 USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep (1999);48:1-59, 61-6.
134. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl. 4):S227-33.
135. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002;17(Suppl. 4): 36-9.
136. Kasiske BL, Zeier MG, Chapman JR et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77: 299-311.
137. Chevrel G, Brantus JF, Sainte-Laudy J, Miossec P. Allergic pancytopenia to trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis. Rheumatology 1999;38:475-6.
138. Nahimana A, Rabodonirina M, Zanetti G et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/ sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 2003;188:1017-23.
139. Huang L, Crothers K, Atzori C et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis 2004;10:1721-8.
140. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000;118:712-20.
141. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-9.
142. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007;357:1874-6.
143. Komano Y, Harigai M, Koike R et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 2009; 61:305-12.
144. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 2011;41:497-502.
145. de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 2011; 13:559-69.
146. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008;59:1034-9.